What is Leerink Partnrs' Forecast for REGENXBIO Q3 Earnings?

Key Points

• Leerink Partners has revised their Q3 2025 earnings estimate for REGENXBIO, projecting a loss of ($1.31) per share, slightly worse than the previous estimate of ($1.30).
• The company reported Q2 earnings of ($1.38) per share, which was below the consensus estimate of ($1.13), with revenues significantly missing expectations at $21.36 million compared to $40.87 million forecasted.
• REGENXBIO currently carries a consensus rating of "Moderate Buy" with a target price of $28.38, despite multiple analysts reducing their price objectives and ratings recently.

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q3 2025 earnings per share estimates for shares of REGENXBIO in a research report issued on Monday, September 15th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings per share of ($1.31) for the quarter, down from their prior forecast of ($1.30). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's Q4 2025 earnings at $0.30 EPS, FY2025 earnings at ($2.27) EPS, FY2026 earnings at ($1.83) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($1.25) EPS and FY2029 earnings at ($1.15) EPS.

RGNX has been the subject of a number of other research reports. Royal Bank Of Canada reduced their price objective on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Chardan Capital reiterated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Monday, September 8th. HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of REGENXBIO in a research report on Monday, September 8th. Wall Street Zen downgraded REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. Finally, Barclays reduced their price objective on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a research report on Friday, August 8th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $28.38.

REGENXBIO Trading Up 3.7%

RGNX traded up $0.33 during midday trading on Wednesday, reaching $9.36. The company's stock had a trading volume of 349,929 shares, compared to its average volume of 483,906. The company has a fifty day simple moving average of $8.78 and a 200 day simple moving average of $8.33. REGENXBIO has a twelve month low of $5.03 and a twelve month high of $13.15. The stock has a market cap of $472.77 million, a P/E ratio of -2.72 and a beta of 1.17.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). The business had revenue of $21.36 million during the quarter, compared to analyst estimates of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%.

Hedge Funds Weigh In On REGENXBIO

Several institutional investors have recently bought and sold shares of RGNX. Jane Street Group LLC raised its position in REGENXBIO by 325.3% in the 4th quarter. Jane Street Group LLC now owns 164,911 shares of the biotechnology company's stock valued at $1,275,000 after purchasing an additional 126,135 shares during the last quarter. Ameriprise Financial Inc. raised its position in REGENXBIO by 4.7% in the 4th quarter. Ameriprise Financial Inc. now owns 284,521 shares of the biotechnology company's stock valued at $2,199,000 after purchasing an additional 12,883 shares during the last quarter. BNP Paribas Financial Markets raised its position in REGENXBIO by 370.1% in the 4th quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock valued at $743,000 after purchasing an additional 75,652 shares during the last quarter. Deutsche Bank AG raised its position in REGENXBIO by 8.5% in the 4th quarter. Deutsche Bank AG now owns 200,375 shares of the biotechnology company's stock valued at $1,549,000 after purchasing an additional 15,722 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in REGENXBIO by 15.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 63,377 shares of the biotechnology company's stock valued at $490,000 after purchasing an additional 8,271 shares during the last quarter. Institutional investors own 88.08% of the company's stock.

Insider Transactions at REGENXBIO

In other REGENXBIO news, CEO Curran Simpson sold 7,734 shares of REGENXBIO stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $10.02, for a total value of $77,494.68. Following the completion of the transaction, the chief executive officer owned 244,597 shares in the company, valued at approximately $2,450,861.94. The trade was a 3.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 12.79% of the company's stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.